Managing risks: successful clinical development in asthma


Asthma is a complex and heterogeneous disease. Patients experience wheezing, shortness of breath, and coughing, frequently occurring during the night or early morning. The condition is characterised by a range of clinical and pathogenic features including variable and recurring symptoms of airflow obstruction, bronchial hyperresponsiveness, mucus hypersecretion, and underlying pulmonary inflammation. The challenges are further exacerbated by the fact that symptoms of asthma can be non-specific and varied. This spectrum of causes and presentations can make the clinical development of new asthma treatments challenging.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member